Twelve serum proteins progressively increase with disease stage in squamous cell cervical cancer patients

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: This study aimed to reliably identify serum protein profile alterations that may be useful for elucidation of the disease mechanism and/or finding new targets for treatment and intervention. Materials and Methods: A total of 1057 women at 4 different squamous cell cervical cancer stages (noninvasive, invasive International Federation of Gynecology and Obstetrics stages I, II, and III) were included in this cross-sectional study. Forty-seven serum proteins were profiled using multiplex Luminex immunoassays. Results: Serum concentration of serum amyloid A (SAA), C-reactive protein (CRP), soluble tumor necrosis factor receptor I and II (sTNFRI and sTNFRII), soluble interleukin 2 receptor α (sIL2Rα), CXCL1, CXCL9, hepatocyte growth factor, squamous cell carcinoma antigen (SCCA), insulin-like growth factor binding protein 2, CA125, and carcinoembryonic antigen (CEA) were elevated significantly as disease progressed in cervical cancer patients. Serum levels are significantly different at early stage (I) for SAA, CRP, sIL2Rα, sTNFRII, SCCA, and CEA (P values ranged from 0.02 for CEA to 0.0001 for CRP and SCCA) and at late stages (II and III) for all 12 proteins (P values ranged from 8.78E-5 for CA125 to 3.49E-47 for SAA), as compared to the noninvasive stage. The areas under the curves of these proteins for disease state separation also improved with the advancement of the disease. The correlations between serum concentrations of these proteins also show different patterns at different clinical stages. These proteins are involved in multiple mechanisms including inflammation and immunity, angiogenesis, growth promotion, and metastasis. Conclusions: A number of serum proteins are significantly different between patients at different stages of cervical cancer.

Original languageEnglish (US)
Pages (from-to)1085-1092
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume24
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Squamous Cell Neoplasms
Serum Amyloid A Protein
Uterine Cervical Neoplasms
Blood Proteins
Carcinoembryonic Antigen
C-Reactive Protein
Interleukin-2 Receptors
CA-125 Antigen
Insulin-Like Growth Factor Binding Protein 2
Proteins
Hepatocyte Growth Factor
Tumor Necrosis Factor Receptors
Serum
Gynecology
Immunoassay
Obstetrics
Area Under Curve
Immunity
Cross-Sectional Studies
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Cervical cancer
  • Immunoassay
  • Inflammation
  • Serum protein profile

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

@article{d3f1d476736043e9a24d54283acaf3c1,
title = "Twelve serum proteins progressively increase with disease stage in squamous cell cervical cancer patients",
abstract = "Objective: This study aimed to reliably identify serum protein profile alterations that may be useful for elucidation of the disease mechanism and/or finding new targets for treatment and intervention. Materials and Methods: A total of 1057 women at 4 different squamous cell cervical cancer stages (noninvasive, invasive International Federation of Gynecology and Obstetrics stages I, II, and III) were included in this cross-sectional study. Forty-seven serum proteins were profiled using multiplex Luminex immunoassays. Results: Serum concentration of serum amyloid A (SAA), C-reactive protein (CRP), soluble tumor necrosis factor receptor I and II (sTNFRI and sTNFRII), soluble interleukin 2 receptor α (sIL2Rα), CXCL1, CXCL9, hepatocyte growth factor, squamous cell carcinoma antigen (SCCA), insulin-like growth factor binding protein 2, CA125, and carcinoembryonic antigen (CEA) were elevated significantly as disease progressed in cervical cancer patients. Serum levels are significantly different at early stage (I) for SAA, CRP, sIL2Rα, sTNFRII, SCCA, and CEA (P values ranged from 0.02 for CEA to 0.0001 for CRP and SCCA) and at late stages (II and III) for all 12 proteins (P values ranged from 8.78E-5 for CA125 to 3.49E-47 for SAA), as compared to the noninvasive stage. The areas under the curves of these proteins for disease state separation also improved with the advancement of the disease. The correlations between serum concentrations of these proteins also show different patterns at different clinical stages. These proteins are involved in multiple mechanisms including inflammation and immunity, angiogenesis, growth promotion, and metastasis. Conclusions: A number of serum proteins are significantly different between patients at different stages of cervical cancer.",
keywords = "Angiogenesis, Cervical cancer, Immunoassay, Inflammation, Serum protein profile",
author = "Wenbo Zhi and Ferris, {Daron Gale} and Sharma, {Ashok Kumar} and Purohit, {Sharad B} and Carlos Santos and Mingfang He and Ghamande, {Sharad A} and Jin-Xiong She",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/IGC.0000000000000153",
language = "English (US)",
volume = "24",
pages = "1085--1092",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Twelve serum proteins progressively increase with disease stage in squamous cell cervical cancer patients

AU - Zhi, Wenbo

AU - Ferris, Daron Gale

AU - Sharma, Ashok Kumar

AU - Purohit, Sharad B

AU - Santos, Carlos

AU - He, Mingfang

AU - Ghamande, Sharad A

AU - She, Jin-Xiong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: This study aimed to reliably identify serum protein profile alterations that may be useful for elucidation of the disease mechanism and/or finding new targets for treatment and intervention. Materials and Methods: A total of 1057 women at 4 different squamous cell cervical cancer stages (noninvasive, invasive International Federation of Gynecology and Obstetrics stages I, II, and III) were included in this cross-sectional study. Forty-seven serum proteins were profiled using multiplex Luminex immunoassays. Results: Serum concentration of serum amyloid A (SAA), C-reactive protein (CRP), soluble tumor necrosis factor receptor I and II (sTNFRI and sTNFRII), soluble interleukin 2 receptor α (sIL2Rα), CXCL1, CXCL9, hepatocyte growth factor, squamous cell carcinoma antigen (SCCA), insulin-like growth factor binding protein 2, CA125, and carcinoembryonic antigen (CEA) were elevated significantly as disease progressed in cervical cancer patients. Serum levels are significantly different at early stage (I) for SAA, CRP, sIL2Rα, sTNFRII, SCCA, and CEA (P values ranged from 0.02 for CEA to 0.0001 for CRP and SCCA) and at late stages (II and III) for all 12 proteins (P values ranged from 8.78E-5 for CA125 to 3.49E-47 for SAA), as compared to the noninvasive stage. The areas under the curves of these proteins for disease state separation also improved with the advancement of the disease. The correlations between serum concentrations of these proteins also show different patterns at different clinical stages. These proteins are involved in multiple mechanisms including inflammation and immunity, angiogenesis, growth promotion, and metastasis. Conclusions: A number of serum proteins are significantly different between patients at different stages of cervical cancer.

AB - Objective: This study aimed to reliably identify serum protein profile alterations that may be useful for elucidation of the disease mechanism and/or finding new targets for treatment and intervention. Materials and Methods: A total of 1057 women at 4 different squamous cell cervical cancer stages (noninvasive, invasive International Federation of Gynecology and Obstetrics stages I, II, and III) were included in this cross-sectional study. Forty-seven serum proteins were profiled using multiplex Luminex immunoassays. Results: Serum concentration of serum amyloid A (SAA), C-reactive protein (CRP), soluble tumor necrosis factor receptor I and II (sTNFRI and sTNFRII), soluble interleukin 2 receptor α (sIL2Rα), CXCL1, CXCL9, hepatocyte growth factor, squamous cell carcinoma antigen (SCCA), insulin-like growth factor binding protein 2, CA125, and carcinoembryonic antigen (CEA) were elevated significantly as disease progressed in cervical cancer patients. Serum levels are significantly different at early stage (I) for SAA, CRP, sIL2Rα, sTNFRII, SCCA, and CEA (P values ranged from 0.02 for CEA to 0.0001 for CRP and SCCA) and at late stages (II and III) for all 12 proteins (P values ranged from 8.78E-5 for CA125 to 3.49E-47 for SAA), as compared to the noninvasive stage. The areas under the curves of these proteins for disease state separation also improved with the advancement of the disease. The correlations between serum concentrations of these proteins also show different patterns at different clinical stages. These proteins are involved in multiple mechanisms including inflammation and immunity, angiogenesis, growth promotion, and metastasis. Conclusions: A number of serum proteins are significantly different between patients at different stages of cervical cancer.

KW - Angiogenesis

KW - Cervical cancer

KW - Immunoassay

KW - Inflammation

KW - Serum protein profile

UR - http://www.scopus.com/inward/record.url?scp=84904210949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904210949&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000153

DO - 10.1097/IGC.0000000000000153

M3 - Article

C2 - 24905620

AN - SCOPUS:84904210949

VL - 24

SP - 1085

EP - 1092

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 6

ER -